Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing ...

Number of tokens unlocked: 11.31 millionAPT Current circulating supply: 558.49 millionAPT On, 2025, Aptos (APT) will unlock 11.31 million tokens,orabout2% of its ...

Aptos partners with Chainlink as it plans to adopt the Chainlink standard for high-quality data to boost its blockchain ...

Basic Attention Token (BAT) is one of the cryptocurrencies that took the crypto space by surprise at launch after completing ...

Aptos integrates Chainlink to enhance dApp scalability and reliability, leveraging secure data feeds for Web3 solutions and ...

Following an already strenuous few days for Bitcoin holders and the crypto market more broadly, fresh news has emerged that the US Department of Justice has ...

HONG KONG SAR - Media OutReach Newswire - 10 January 2025 - Today, IX Asia Indexes announced the 2024 4th quarter review of ixCrypto Index Series and IX Digital Asset ...

If the demand zone triggers another rally, APT could surge by 76.17%, potentially reaching $15.33. However, if APT fails to ...

Aptos integrates Chainlink Data Feeds to deliver trusted off-chain data, enhancing scalability, reliability, and security for ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Aptose Biosciences (APTO) announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib in combination with ...

TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AMLSAN DIEGO and ...